Locally Recurrent Prostate Cancer
Conditions
Keywords
prostate cancer, locally recurrent, PRX302
Brief summary
The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate. Therapeutic activity will be determined based on changes in PSA levels, PSA velocity, PSA doubling time and tumor burden following treatment.
Interventions
DRUGPRX302
Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
Sponsors
Sophiris Bio Corp
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Completed a full course of radiation therapy for prostate cancer at least 2 years before enrollment. * Biochemical failure at screening as determined by either the ASTRO or the Phoenix definitions. * At least 5 available PSA readings after completion of radiation therapy and prior to screening. * PSA level of not greater than 10 ng/mL. * PSA doubling time of at least 9 months at screening. * Biopsy-proven recurrent localized prostate cancer. * Tumor stage T1C to T2C. * Prostate volume estimated at 40 mL or less as determined by TRUS. * ECOG performance score 0 to 2. * Serum testosterone of at least 1 ng/dL.
Exclusion criteria
* Prior history of metastatic prostate cancer. * Salvage external beam therapy and/or salvage brachytherapy prior to enrollment. * Biological, immunological, chemotherapeutic treatment or cryotherapy after completing radiation. * Androgen ablation therapy within 12 months prior to enrollment. * Recurrence of prostate cancer within 18 months of definitive primary radiotherapy. * Other medication for prostate cancer. * Presence of active malignancy other than prostate cancer. * Treatment with other investigational therapies within 12 months prior to enrolment. * Presence of a chronic indwelling Foley catheter for obstructive uropathy. * Previous transurethral resection of the prostate (TURP), transurethral resection of the bladder neck, photo-selective vaporization of the prostate (PVP) or other resection surgery in the urinary tract. * Previous treatment with PRX302. * Any evidence of metastatic disease on bone scan, CT or magnetic resonance imaging (MRI) within 3 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA levels, PSA doubling time, PSA velocity and tumor burden assessment by biopsy compared to screening. | Day 45 and Day 180 |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability of PRX302. | 12 months. |
Countries
United States
Outcome results
None listed